DNA repair deficiency as circulating biomarker in prostate cancer
Deleterious aberrations in DNA repair genes are actionable in approximately 25% of metastatic castration-resistant prostate cancers (mCRPC) patients. Homology recombination repair (HRR) is the DNA damage repair (DDR) mechanism most frequently altered in prostate cancer; of note BRCA2 is the most fre...
Main Authors: | Martina Catalano, Daniele Generali, Marta Gatti, Barbara Riboli, Leda Paganini, Gabriella Nesi, Giandomenico Roviello |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1115241/full |
Similar Items
-
Circulating Tumor DNA Analysis on Metastatic Prostate Cancer with Disease Progression
by: Sungun Bang, et al.
Published: (2023-08-01) -
Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential
by: Marianne Trier Bjerre, et al.
Published: (2020-05-01) -
Clinical Applications of Liquid Biopsy in Prostate Cancer: From Screening to Predictive Biomarker
by: Filip Ionescu, et al.
Published: (2022-03-01) -
Circulating Tumour DNA as a Biomarker Source in Metastatic Prostate Cancer
by: Gillian Vandekerkhove, Alexander Wyatt
Published: (2020-10-01) -
Overcoming Obstacles in Liquid Biopsy Developments for Prostate Cancer
by: Jang A, et al.
Published: (2022-08-01)